{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:59:29Z","timestamp":1789185569551,"version":"build-2803163510"},"reference-count":29,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Academic Emergency Medicine"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Emergency department (ED) patients with serious skin and soft tissue infections (SSTIs) are often hospitalized to receive intravenous (IV) antibiotics. Appropriate patients may avoid admission following a single\u2010dose, long\u2010acting IV antibiotic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a preintervention versus postintervention design trial at 11 U.S. EDs comparing hospitalization rates under usual care to those using a clinical pathway that included a single IV dalbavancin dose. We enrolled adults with cellulitis, abscess, or wound infection with an infected area of \u226575\u00a0cm\n                      <jats:sup>2<\/jats:sup>\n                      without other indications for hospitalization. Clinical pathway participants discharged from the ED received a 24\u2010hour follow\u2010up telephone call and had a 48\u2010 to 72\u2010hour in\u2010person visit. We hypothesized that, compared to usual care, the clinical pathway would result in a significant reduction in the initial hospitalization rate.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 156 and 153 participants in usual care and clinical pathway periods, median infection areas were 255.0 (interquartile range [IQR]\u00a0= 150.0 to 500.0) cm\n                      <jats:sup>2<\/jats:sup>\n                      and 289.0 (IQR\u00a0= 161.3 to 555.0) cm\n                      <jats:sup>2<\/jats:sup>\n                      , respectively. During their initial care, 60 (38.5%) usual care participants were hospitalized and 27 (17.6%) pathway participants were hospitalized (difference\u00a0= 20.8 percentage points [PP], 95% confidence interval [CI]\u00a0= 10.4 to 31.2 PP). Over 44\u00a0days, 70 (44.9%) usual care and 44 (28.8%) pathway participants were hospitalized (difference\u00a0= 16.1 PP, 95% CI\u00a0= 4.9 to 27.4 PP).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Implementation of an ED SSTI clinical pathway for patient selection and follow\u2010up that included use of a single\u2010dose, long\u2010acting IV antibiotic was associated with a significant reduction in hospitalization rate for stable patients with moderately severe infections.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Registration:<\/jats:bold>\n                      NCT02961764.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/acem.14258","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T13:50:46Z","timestamp":1617025846000},"page":"1108-1117","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pathway with single\u2010dose long\u2010acting intravenous antibiotic reduces emergency department hospitalizations of patients with skin infections"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7048-8086","authenticated-orcid":false,"given":"David A.","family":"Talan","sequence":"first","affiliation":[{"name":"Ronald Reagan UCLA Medical Center David Geffen School of Medicine at the University of California at Los Angeles Los Angeles CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Mower","sequence":"additional","affiliation":[{"name":"Ronald Reagan UCLA Medical Center David Geffen School of Medicine at the University of California at Los Angeles Los Angeles CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank A.","family":"Lovecchio","sequence":"additional","affiliation":[{"name":"Valleywise Health ASU University of Arizona and Creighton College of Medicine Phoenix Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Rothman","sequence":"additional","affiliation":[{"name":"Johns Hopkins Medical Center Johns Hopkins School of Medicine Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Steele","sequence":"additional","affiliation":[{"name":"Truman Medical Center University of Missouri\u2013Kansas City School of Medicine Kansas City Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn","family":"Keyloun","sequence":"additional","affiliation":[{"name":"AbbVie Inc Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Gillard","sequence":"additional","affiliation":[{"name":"AbbVie Inc Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Copp","sequence":"additional","affiliation":[{"name":"ICON plc Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Moran","sequence":"additional","affiliation":[{"name":"Olive View UCLA Medical Center David Geffen School of Medicine at the University of California at Los Angeles Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,5,5]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2007.12.004"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1509.081228"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-296"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2013.1318"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2014.941065"},{"key":"e_1_2_10_7_1","volume-title":"IDWeek Annual Meeting","author":"LaPensee KT","year":"2012"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2018.09.020"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.5811\/westjem.2014.11.24133"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu778"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1086\/497271"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310422"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ982"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0666-0"},{"issue":"44","key":"e_1_2_10_15_1","first-page":"183","article-title":"Clinical pathway for moderate to severe acute bacterial skin and skin structure infections from a US perspective: a roundtable discussion","volume":"2016","author":"Bosso JA","year":"1995","journal-title":"Hosp Pract"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2014.12.001"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1086\/420939"},{"key":"e_1_2_10_18_1","volume-title":"Hospital Medicine 2018","author":"Gunderson CG","year":"2018"},{"key":"e_1_2_10_19_1","unstructured":"US Department of Health and Human Services US Food and Drug Administration Center for Drug Evaluation and Research (CDER).Guidance for Industry. Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment. 2013. Accessed March 4 2020.https:\/\/www.fda.gov\/files\/drugs\/published\/Acute\u2010Bacterial\u2010Skin\u2010and\u2010Skin\u2010Structure\u2010Infections\u2010\u2010\u2010Developing\u2010Drugs\u2010for\u2010Treatment.pdf"},{"key":"e_1_2_10_20_1","unstructured":"Dalvance\u00ae(dalbavancin).Full Prescribing Information Durata Therapeutics US Ltd. Parsippany NJ 2018."},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw177"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.5653"},{"key":"e_1_2_10_24_1","unstructured":"Reilly Associates.WPAI:SHP V2.0.2010. Accessed October 21 2019.http:\/\/www.reillyassociates.net\/WPAI_SHP.html."},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199603000-00003"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.6.749"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1086\/653523"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.0884"},{"key":"e_1_2_10_29_1","unstructured":"Dalvance \u2010 Micromedex Solutions.Truven Health Analytics Inc. c2021. Accessed May 20 2019. http:\/\/www.micromedexsolutions.com."},{"key":"e_1_2_10_30_1","unstructured":"Kaiser Family Foundation.Hospital Adjusted Expenses per Inpatient Day by Ownership.2018. Accessed June 27 2019. https:\/\/www.kff.org\/health\u2010costs\/state\u2010indicator\/expenses\u2010per\u2010inpatient\u2010day\u2010by\u2010ownership\/?currentTimeframe\u00a0= 0&sortModel\u00a0= %7B%22colId%22:%22Location%22 %22sort%22:%22asc%22%7D"}],"container-title":["Academic Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/acem.14258","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/acem.14258","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/acem.14258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T18:33:50Z","timestamp":1693334030000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/acem.14258"}},"subtitle":[],"editor":[{"given":"Damon R.","family":"Kuehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,5,5]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1111\/acem.14258"],"URL":"https:\/\/doi.org\/10.1111\/acem.14258","archive":["Portico"],"relation":{},"ISSN":["1069-6563","1553-2712"],"issn-type":[{"value":"1069-6563","type":"print"},{"value":"1553-2712","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,5]]},"assertion":[{"value":"2020-10-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}